医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata Partners with Leading Korean CRO C&R Research to Optimize Study Operations and Data Quality Across Clinical Development Programs in Asia

2015年12月02日 AM07:30
このエントリーをはてなブックマークに追加


 

NEW YORK & SEOUL, South Korea

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and C&R Research (C&R), a leading South Korean full-service contract research organization (CRO), today announced that the Medidata Clinical Cloud® platform has been adopted to improve operational efficiencies, resource savings and decision-making processes across C&R’s entire R&D portfolio in Asia. As part of its company-wide initiative to achieve cutting-edge productivity, C&R is partnering with Medidata and leveraging its industry-leading electronic data capture and management technology, as well as the company’s best-in-class solution for risk-based monitoring (RBM)—a proven methodology for reducing trial costs while providing a higher level of clinical data accuracy and quality.

“South Korea has quickly become a key hub for multinational clinical trials, and we at C&R are committed to ensuring we support our local and global biopharmaceutical customers’ R&D programs with the most innovative technologies,” said Moon Tae Yoon, president of C&R. “Partnering with a technology company that has deep life sciences expertise is essential to our success, and Medidata really understands our mission and R&D needs. The Medidata platform—which includes a holistic risk-based monitoring solution—is helping us improve operational efficiencies and decision-making processes throughout the clinical trial lifecycle, and provides us with the flexibility and scalability we need to accelerate progress across all of our clinical development programs.”

Founded in 1997 as the first CRO in South Korea, C&R provides a full range of clinical trial and regulatory affairs services. The Seoul-based organization—which specializes in oncology, biologic agents, pharmacovigilance and post-market surveillance, among other areas—supports Phase I-III and post-approval (Phase IV to observational) clinical research. To optimize R&D operations for speed, resource saving and data quality, C&R has adopted Medidata’s cloud-based technology for electronic data capture (EDC) Medidata Rave® as its enterprise EDC solution across its entire portfolio of clinical research services. Additionally, C&R is adopting Medidata RBM, a robust combination of technology, analytics and hands-on strategic consulting services that enable life science organizations to quickly realize the quality, cost and timeline benefits of a comprehensive RBM program.

“C&R brings a wealth of knowledge to the clinical development landscape in South Korea and the broader Asia-Pacific (APAC) region, and we’re very happy to welcome the organization as a Medidata partner,” said Takeru Yamamoto, Medidata’s managing director of APAC. “We look forward to continue collaborating with the C&R team as they further expand and enhance their clinical development programs powered by our innovative technology—helping pharma and biotechnology companies deliver high-quality therapies to the patients we all serve.”

Connect with Medidata

About C&R Research

C&R Research Inc., founded in 1997, is Korea’s first Contract Research Organization (CRO). Since its inception, C&R Research has been providing clinical services to pharmaceuticals, biotech and medical device companies who require medical consultation for before/after stage of clinical trials for new drug and new product development. In addition, C&R Research has been offering competitive and differentiated services through its own anti-cancer drug clinical research team, the “Oncology Team” and its Late Phase Study team, the “LPS Team”.

C&R Research aims to contribute to CRO industry and continuous growth of global pharmaceutical industry through its full-scope services in clinical trials.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151201006730/en/

CONTACT

Medidata
Investor:
Medidata
Solutions
Hulus Alpay, +1 212-419-1025
halpay@mdsol.com
or
Media
– Americas & EMEA
:
Medidata Solutions
Nicole
Pariser, +1 212-659-1069
npariser@mdsol.com
or
Media
– APAC
:
Medidata Solutions
Da Jeong Chong, + 82
2 2015 7715
dchong@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda’s Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases
  • Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke
  • Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
  • ANK免疫細胞療法の治療経過を学会発表
  • 美泰在其营养补剂中添加真芦荟的古老力量